Partnering Opportunities

Bio-Path seeks to apply DNAbilize®, our proprietary neutral-lipid delivery technology, to new protein targets in cancer and other disease indications.

We are interested in pursuing a wide-ranging, proactive licensing program to include co-development of specific liposomal antisense drug candidates; sub-license the delivery template for outside development of liposomal antisense drug candidates; or out-license a partially developed drug for final development and marketing.

Please contact us at if you are interested in partnering opportunities.

Licensing and collaborations:

Suzanne Kennedy, Ph.D.
Director of Corporate Development
(832) 742-1357

Investor Inquiries:

Will O’Connor
Stern Investor Relations
(212) 362-1200

Delivering a Better Path for Cancer Patients.